2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2427

Attainment of Low Disease Activity Is Predictive of Maintenance of Disease Control upon Adalimumab Discontinuation for Two Years Following Combination Therapy in Japanese Patients with Early Rheumatoid Arthritis
Abstract Number: 2935

Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis
Abstract Number: 1732

Attenuation of Sclerodermatous Graft Versus Host Disease (sclGVHD) in IL4RA Receptor-Deficient Mice
Abstract Number: 2662

Attribution Protocol and Clinical Significance of Neuropsychiatric Manifestations in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 1626

Autoantibodies Against High Mobility Group Box 1 (HMGB1) in Patients with SLE
Abstract Number: 2782

Autoantibodies from Single Circulating Plasmablasts React with Citrullinated Antigens and Porphyromonas Gingivalis in Rheumatoid Arthritis
Abstract Number: 320

Autoantibodies in Juvenile Systemic Sclerosis
Abstract Number: 2541

Autoantibodies in Pediatric Sjogren’s Patients
Abstract Number: 2985

Autoantibodies to 14-3-3η Are Novel Biomarkers Associated with Inflammation and Radiographic Progression in Ankylosing Spondylitis
Abstract Number: 3004

Autoantibody-Mediated Raynaud’s Phenomenon: Animal Model and Human Disease
Abstract Number: 703

Autoimmune Hepatitis in Systemic Lupus Erythematosus
Abstract Number: 2252

Autoimmune Thyroid Disease Is Associated with a Higher Frequency of Spinal Degenerative Disc Disease
Abstract Number: 1530

Autologous Tolerogenic Dendritic Cells for Rheumatoid and Inflammatory Arthritis
Abstract Number: 149

Automated Digital Analysis of Major Salivary Gland Ultrasound Images
Abstract Number: 2147

Automatically Extracted Quantitative Biomarkers for Assessing Connective Tissue Disease Using Nailfold Capillaroscopy

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].